Purple Biotech (PPBT) Payables (2017 - 2021)

Purple Biotech (PPBT) has disclosed Payables for 5 consecutive years, with $1.5 million as the latest value for Q4 2021.

  • On a quarterly basis, Payables rose 22.95% to $1.5 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.5 million, a 22.95% increase, with the full-year FY2021 number at $1.5 million, up 22.95% from a year prior.
  • Payables was $1.5 million for Q4 2021 at Purple Biotech, up from $1.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.5 million in Q4 2021 to a low of $215000.0 in Q4 2017.
  • A 5-year average of $967200.0 and a median of $1.2 million in 2020 define the central range for Payables.
  • Peak YoY movement for Payables: skyrocketed 227.91% in 2018, then fell 3.78% in 2020.
  • Purple Biotech's Payables stood at $215000.0 in 2017, then surged by 227.91% to $705000.0 in 2018, then skyrocketed by 76.6% to $1.2 million in 2019, then decreased by 3.78% to $1.2 million in 2020, then grew by 22.95% to $1.5 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Payables are $1.5 million (Q4 2021), $1.2 million (Q4 2020), and $1.2 million (Q4 2019).